Independence Bank of Kentucky Has $150,000 Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Independence Bank of Kentucky increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 286 shares of the biopharmaceutical company’s stock after purchasing an additional 55 shares during the period. Independence Bank of Kentucky’s holdings in Regeneron Pharmaceuticals were worth $150,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in REGN. Brighton Jones LLC grew its stake in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the period. Centaurus Financial Inc. grew its stake in shares of Regeneron Pharmaceuticals by 63.3% during the fourth quarter. Centaurus Financial Inc. now owns 196 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 76 shares during the period. Versant Capital Management Inc grew its stake in shares of Regeneron Pharmaceuticals by 334.6% during the first quarter. Versant Capital Management Inc now owns 226 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 174 shares during the period. Fifth Third Wealth Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 23.5% during the first quarter. Fifth Third Wealth Advisors LLC now owns 1,357 shares of the biopharmaceutical company’s stock worth $861,000 after purchasing an additional 258 shares during the period. Finally, Rhumbline Advisers grew its stake in Regeneron Pharmaceuticals by 1.5% in the first quarter. Rhumbline Advisers now owns 173,167 shares of the biopharmaceutical company’s stock valued at $109,828,000 after acquiring an additional 2,547 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on REGN shares. Rothschild & Co Redburn started coverage on Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They issued a “buy” rating and a $890.00 target price for the company. Redburn Atlantic raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Citigroup reissued a “buy” rating and issued a $650.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Morgan Stanley reissued an “overweight” rating and issued a $761.00 target price (up from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $817.67.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $560.75 on Tuesday. The firm has a market cap of $59.43 billion, a price-to-earnings ratio of 14.13, a price-to-earnings-growth ratio of 1.80 and a beta of 0.35. The stock’s 50-day moving average is $570.09 and its 200-day moving average is $568.76. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,061.60. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same period in the previous year, the company posted $11.56 earnings per share. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.